Drugs / Fumaderm
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02955693 | Sep → Oct 2016 | psoriasis | Almirall, S.A. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03255382 Comparator | Aug 2017 → Jul 2018 | psoriasis | AbbVie | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fumaderm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03255382 ↗ |
| Route | Oral | “Fumaderm tablet administered orally” NCT03255382 ↗ |